Body Composition Peptides

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks. Currently in Phase 3 development.

MK-677 (Ibutamoren) is an orally active, non-peptide growth hormone secretagogue that mimics the action of ghrelin at the GHS-R1a receptor. Research focuses on increasing GH and IGF-1 levels, improving sleep quality, body composition, and bone density.

CJC-1295 is a synthetic GHRH (Growth Hormone-Releasing Hormone) analog with extended duration due to Drug Affinity Complex technology. Studied for its effects on growth hormone release and body composition.

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting GHRH analog that uses a maleimidopropionic acid linker to bind serum albumin, extending its half-life to several days. This provides sustained GH elevation compared to the shorter-acting Mod GRF 1-29 (CJC-1295 without DAC).

IGF-1 LR3 (Long R3 IGF-1) is a modified analog of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino-acid extension. These modifications reduce IGF binding protein affinity, increasing potency and half-life compared to native IGF-1.

Sermorelin is a synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH). It was FDA-approved for pediatric growth hormone deficiency and is widely used off-label for anti-aging and body composition optimization.

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog used for reducing visceral adipose tissue in patients with lipodystrophy. Marketed as Egrifta. Specifically targets deep abdominal fat accumulation.

Ipamorelin is a selective growth hormone secretagogue developed by Novo Nordisk. It stimulates GH release without significantly affecting cortisol or prolactin levels. Has been studied in clinical trials for postoperative recovery.

GHRP-6 (Growth Hormone Releasing Peptide-6) is a hexapeptide that stimulates growth hormone release through the ghrelin receptor. Known for potent GH release but also significant appetite stimulation.

Follistatin is a naturally occurring glycoprotein that binds and inhibits myostatin, a negative regulator of muscle growth. Studied for muscle wasting conditions and performance enhancement. Gene therapy approaches also in development.

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme linked to obesity and metabolic dysfunction. Research focuses on fat cell metabolism, weight loss, and reversing diet-induced obesity in preclinical models.

HGH Fragment 176-191 is a stabilized fragment of the C-terminal portion of human growth hormone (amino acids 176-191). It is the parent compound of AOD-9604. Research focuses on fat metabolism and lipolysis without the growth-promoting or diabetogenic effects of full GH.

MGF (Mechano Growth Factor) is a splice variant of the IGF-1 gene produced in response to mechanical loading of muscle tissue. Also known as IGF-1Ec in humans. Research focuses on muscle repair, satellite cell activation, and recovery from exercise-induced damage.

AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 176-191). Originally developed as an anti-obesity agent. Shows preclinical evidence for promoting fat metabolism without affecting blood sugar or growth.

Hexarelin is a synthetic hexapeptide growth hormone secretagogue, considered one of the most potent GHRPs available. Also shows cardioprotective properties independent of GH release.

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that stimulates growth hormone secretion. Considered more potent than GHRP-6 with less appetite stimulation.